Search

Your search keyword '"B. Crestani"' showing total 665 results
Start Over Author "B. Crestani"
665 results on '"B. Crestani"'

1. The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study

Author

L. Plantier, A. Smolinska, R. Fijten, M. Flamant, J. Dallinga, J. J. Mercadier, D. Pachen, M. P. d’Ortho, F. J. van Schooten, B. Crestani, and A. W. Boots

Subjects
Volatile organic compound (VOC), Idiopathic pulmonary fibrosis (IPF), Connective tissue disease associated-ILD (CTD-ILD), Diagnostic profiles, Gas chromatography–time of flight–mass spectrometry (GC-tof–MS), Diseases of the respiratory system, RC705-779
Abstract

Abstract Background Fibrotic Interstitial lung diseases (ILD) are a heterogeneous group of chronic lung diseases characterized by diverse degrees of lung inflammation and remodeling. They include idiopathic ILD such as idiopathic pulmonary fibrosis (IPF), and ILD secondary to chronic inflammatory diseases such as connective tissue disease (CTD). Precise differential diagnosis of ILD is critical since anti-inflammatory and immunosuppressive drugs, which are beneficial in inflammatory ILD, are detrimental in IPF. However, differential diagnosis of ILD is still difficult and often requires an invasive lung biopsy. The primary aim of this study is to identify volatile organic compounds (VOCs) patterns in exhaled air to non-invasively discriminate IPF and CTD-ILD. As secondary aim, the association between the IPF and CTD-ILD discriminating VOC patterns and functional impairment is investigated. Methods Fifty-three IPF patients, 53 CTD-ILD patients and 51 controls donated exhaled air, which was analyzed for its VOC content using gas chromatograph- time of flight- mass spectrometry. Results By applying multivariate analysis, a discriminative profile of 34 VOCs was observed to discriminate between IPF patients and healthy controls whereas 11 VOCs were able to distinguish between CTD-ILD patients and healthy controls. The separation between IPF and CTD-ILD could be made using 16 discriminating VOCs, that also displayed a significant correlation with total lung capacity and the 6 min’ walk distance. Conclusions This study reports for the first time that specific VOC profiles can be found to differentiate IPF and CTD-ILD from both healthy controls and each other. Moreover, an ILD-specific VOC profile was strongly correlated with functional parameters. Future research applying larger cohorts of patients suffering from a larger variety of ILDs should confirm the potential use of breathomics to facilitate fast, non-invasive and proper differential diagnosis of specific ILDs in the future as first step towards personalized medicine for these complex diseases.

Published
2022
Full Text
View/download PDF

2. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events

Author

Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, Jérémy Jaffré, Hugo Langris, Valérie Pourcher, Frédéric Schramm, Nadine Lemaître, Jérôme Robert, O. Bouchaud, T. Billard-Pomares, E. Carbonnelle, F. Mechaï, H. Nunes, M. Pellan, A.-S. Morin, C. Dumesnil, J. Dumoulin, A.-L. Roux, M. Jachym, D. le Du, D. Marigot-Outtandy, S. Abgrall, V. Chambrin, C. Guillet, B. Fantin, A. Galy, J.-W. Decousser, J.D. Lelièvre, S. Gallien, B. Nebbad-Lechani, L. Deconinck, S. Bulifon, N. Fortineau, B. Wyplosz, F. Cohen, N. Lemaitre, B. Crestani, N. Grall, C. Pierre-Audigier, C. Rioux, Y. Yazdanpanah, C. Le Jeunne, P. Morand, N. Roche, J. Pavie, P. Loulergue, V. Delcey, E. Lecorché, A.-L. Munier, F. Mougari, P. Sellier, E. Bille, A. Ferroni, R. Guéry, A. Hummel, J. Lourenco, A. Aubry, I. Bonnet, E. Caumes, C. Londner, F. Morel, K. Lacombe, V. Lalande, J.-L. Meynard, N. Veziris, N. De Castro, B. Denis, M. Lafaurie, J.-M. Molina, A. Canestri, L. Lassel, G. Pialoux, C. Verdet, A.-L. Nardi, M. Gominet, and E. Catherinot

Subjects
Tuberculosis, Isoniazid, Drug resistance, Risk factors, Epidemiology, Infectious and parasitic diseases, RC109-216
Abstract

Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.

Published
2021
Full Text
View/download PDF

3. Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients

Author

C. Daccord, V. Cottin, G. Prévot, Y. Uzunhan, J. F. Mornex, P. Bonniaud, R. Borie, A. Briault, M. A. Collonge-Rame, B. Crestani, G. Devouassoux, O. Freynet, A. Gondouin, P. A. Hauss, C. Khouatra, S. Leroy, S. Marchand-Adam, C. Marquette, D. Montani, J. M. Naccache, G. Nadeau, N. Poulalhon, M. Reynaud-Gaubert, M. Salaun, B. Wallaert, J. F. Cordier, M. Faouzi, R. Lazor, and the OrphaLung network

Subjects
Birt-Hogg-Dube syndrome, FLCN protein, human, Respiratory function tests, Pleurodesis, Medicine
Abstract

Abstract Background Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder caused by mutations in the FLCN gene coding for folliculin. Its clinical expression includes cutaneous fibrofolliculomas, renal tumors, multiple pulmonary cysts, and recurrent spontaneous pneumothoraces. Data on lung function in BHD are scarce and it is not known whether lung function declines over time. We retrospectively assessed lung function at baseline and during follow-up in 96 patients with BHD. Results Ninety-five percent of BHD patients had multiple pulmonary cysts on computed tomography and 59% had experienced at least one pneumothorax. Mean values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and total lung capacity were normal at baseline. Mean (standard deviation) residual volume (RV) was moderately increased to 116 (36) %pred at baseline, and RV was elevated > 120%pred in 41% of cases. Mean (standard deviation) carbon monoxide transfer factor (DLco) was moderately decreased to 85 (18) %pred at baseline, and DLco was decreased

Published
2020
Full Text
View/download PDF

4. Pulmonary alveolar proteinosis

Author

B. Crestani, R. Epaud, M. Aubier, M-C. Dombret, C. Taille, M-P. Debray, C. Danel, and R. Borie

Subjects
Granulocyte macrophage-colony stimulating factor, macrophage, pulmonary lavage, rituximab, surfactant, Diseases of the respiratory system, RC705-779
Abstract

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar accumulation of surfactant. It may result from mutations in surfactant proteins or granulocyte macrophage-colony stimulating factor (GM-CSF) receptor genes, it may be secondary to toxic inhalation or haematological disorders, or it may be auto-immune, with anti-GM-CSF antibodies blocking activation of alveolar macrophages. Auto-immune alveolar proteinosis is the most frequent form of PAP, representing 90% of cases. Although not specific, high-resolution computed tomography shows a characteristic “crazy paving” pattern. In most cases, bronchoalveolar lavage findings establish the diagnosis. Whole lung lavage is the most effective therapy, especially for auto-immune disease. Novel therapies targeting alveolar macrophages (recombinant GM-CSF therapy) or anti-GM-CSF antibodies (rituximab and plasmapheresis) are being investigated. Our knowledge of the pathophysiology of PAP has improved in the past 20 yrs, but therapy for PAP still needs improvement.

Published
2011

5. Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjögren's syndrome

Author

A. C. Henriet, E. Diot, S. Marchand-Adam, A. de Muret, O. Favelle, B. Crestani, and P. Diot

Subjects
Connective tissue disease, organising pneumonia, Sjögren's syndrome, Diseases of the respiratory system, RC705-779
Abstract

Connective tissue diseases are known to be one of the causes of organising pneumonia (OP). However, this association is rare and signs of OP usually occur in the context of an already diagnosed disease. We report three cases of OP preceding the articular symptoms of the underlying connective tissue disease by 3–6 months in two cases of rheumatoid arthritis and by 36 months in one patient with primary Sjögren's syndrome. The diagnosis of post-infectious OP had initially been suspected in the three cases and the patients had not been followed up further. The occurrence of OP preceding articular or any other extrapulmonary involvement of connective tissue disease had been reported in only four cases in the literature and, to our knowledge, no case preceding Sjögren's syndrome had ever been reported. These observations suggest that exhaustive investigations should be considered when OP is diagnosed, including antinuclear auto-antibodies and investigations for Sjögren's syndrome, even when there are no clinical signs suggesting an underlying connective tissue disease. These investigations should also be repeated during the course of the disease, especially in the case of OP continuing to progress under treatment and, of course, if signs of connective tissue disease appear.

Published
2010

6. Retrosternal and pleural 'bridging' fibrosis mimicking malignancy in a patient exposed to asbestos

Author

M-P. Debray, S. Marchand-Adam, R. Soufan, J. Ostinelli, P-Y. Brillet, E. Schouman-Claeys, and B. Crestani

Subjects
Asbestos exposure, computed tomography, mediastinal fibrosis, positron emission tomography, Diseases of the respiratory system, RC705-779
Abstract

Mediastinal fibrosis is a rare, benign disorder characterised by proliferation of fibrous tissue within the mediastinum. It can present as diffuse mediastinal infiltration or, more frequently, as a localised soft tissue mass, usually in the right paratracheal or subcarinal areas. 18-fluorodeoxyglucose (18-FDG) positron emission tomography (PET) imaging has only been reported in a few case reports with variable aspects. Herein, we present an unusual pattern of mediastinal fibrosis, presenting as a thick retrosternal mass contiguous with pleural thickening. 18-FDG PET showed intensely increased uptake in the mass. Both the location of fibrosis and PET imaging were confusing with malignancy. Histopathological proof of benign fibrosis was obtained by surgery. The patient had been exposed to asbestos and the possible relationship of this particular pattern of fibrosis with asbestos exposure will be discussed.

Published
2010

12. Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022

Author

J. Le Pavec, C. Pison, S. Hirschi, V. Bunel, P. Mordant, O. Brugière, M. Le Guen, A. Olland, B. Coiffard, B. Renaud-Picard, A. Tissot, G. Brioude, R. Borie, B. Crestani, G. Deslée, S. Stelianides, H. Mal, A. Schuller, L. Falque, G. Lorillon, A. Tazi, P.R. Burgel, D. Grenet, S. De Miranda, A. Bergeron, D. Launay, V. Cottin, H. Nunes, D. Valeyre, Y. Uzunhan, G. Prévot, O. Sitbon, D. Montani, L. Savale, M. Humbert, E. Fadel, O. Mercier, J.F. Mornex, G. Dauriat, and M. Reynaud-Gaubert

Subjects
Pulmonary and Respiratory Medicine
Published
2022

13. Exemples de partenariats réussis d'une cohorte de maladie rare

Author

V. Cottin, S. Guéguen, H. Nunes, S. Jouneau, B. Crestani, P. Bonniaud, L. Wemeau, D. Israël-Biet, M. Reynaud-Gaubert, A. Gondouin, J. Cadranel, S. Marchand-Adam, M.K. Bramki, I. Dufaure-Garé, S. Amselem, A. Clément, and null RaDiCo team

Subjects
Epidemiology, Public Health, Environmental and Occupational Health
Published
2022

14. Télomères et poumon

Author

C. Guérin, B. Crestani, C. Dupin, L. Kawano-Dourado, I. Ba, C. Kannengiesser, and R. Borie

Subjects
Pulmonary and Respiratory Medicine
Published
2022

17. Updated indications and contraindications in 2022 for lung transplantation in France

Author

J, Le Pavec, C, Pison, S, Hirschi, V, Bunel, P, Mordant, O, Brugière, M, Le Guen, A, Olland, B, Coiffard, B, Renaud-Picard, A, Tissot, G, Brioude, R, Borie, B, Crestani, G, Deslée, S, Stelianides, H, Mal, A, Schuller, L, Falque, G, Lorillon, A, Tazi, P R, Burgel, D, Grenet, S, De Miranda, A, Bergeron, D, Launay, V, Cottin, H, Nunes, D, Valeyre, Y, Uzunhan, G, Prévot, O, Sitbon, D, Montani, L, Savale, M, Humbert, E, Fadel, O, Mercier, J F, Mornex, G, Dauriat, M, Reynaud-Gaubert, Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay, Hôpital Marie-Lannelongue, Université Paris-Sud - Paris 11 (UP11), Université Grenoble Alpes (UGA), Service de pneumologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Nouvel Hôpital Civil de Strasbourg, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Chirurgie thoracique et transplantation pulmonaire [Suresnes] (CT2P - Hôpital Foch), Hôpital Foch [Suresnes], ERAMET (ERAMET), Service de chirurgie thoracique, CHU Bordeaux [Bordeaux], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Aix Marseille Université (AMU), Hôpital Nord [CHU - APHM], Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Université de Strasbourg (UNISTRA), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) (U1064 Inserm - CR2TI), Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de réadaptation [Achères] (IR), CIC Hôpital Bichat, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-UFR de Médecine, Pôle Thorax et Vaisseaux [CHU Grenoble], Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Service de pneumologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpitaux Universitaires de Genève (HUG), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pneumologie [Avicenne], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie de l'Insecte : Signalisation et Communication (PISC), Institut National de la Recherche Agronomique (INRA)-Université Pierre et Marie Curie - Paris 6 (UPMC)-AgroParisTech, Service de Pneumologie [AP-HP Hôpital Avicenne, Bobigny], Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Bicêtre, Centre Chirurgical Marie Lannelongue (CCML), Université Paris-Saclay, UMR INRA / ENV Lyon / Univ. Lyon 1 : Lentivirus des petits ruminants, Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), and Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille)

Subjects
Emergency registration, MESH: Respiratory Insufficiency* / etiology, MESH: France / epidemiology, MESH: Humans, Survival, Contraindications, [SDV]Life Sciences [q-bio], MESH: Quality of Life, Super urgence, MESH: Lung Transplantation* / methods, Contre-indication, Indication, List, Lung transplantation, Survie, Quality of Life, Humans, Transplantation pulmonaire, France, Inscription sur liste, Respiratory Insufficiency, MESH: Contraindications
Abstract

International audience; Lung transplantation (LTx) is the last-resort treatment for end-stage respiratory insufficiency, whatever its origin, and represents a steadily expanding field of endeavor. Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been made to meet the challenges raised by surgical management, perioperative care, and long-term medical complications. The number of procedures has increased, leading to improved post-LTx prognosis. One consequence of these multiple developments has been a pruning away of contraindications over time, which has, in some ways, complicated the patient selection process. With these considerations in mind, the Francophone Pulmonology Society (Société de Pneumology de Langue Française [SPLF]) has set up a task force to produce up-to-date working guidelines designed to assist pulmonologists in managing end-stage respiratory insufficiency, determining which patients may be eligible for LTx, and appropriately timing LTx-center referral. The task force has examined the most recent literature and evaluated the risk factors that continue to limit patient survival after LTx. Ideally, the objectives of LTx are to prolong life while improving quality of life. The guidelines developed by the task force apply to a limited resource and are consistent with the ethical principles described below.; La transplantation pulmonaire (TxP) constitue le traitement ultime de l’insuffisance respiratoire terminale quelle qu’en soit l’origine et voit son activité en permanente expansion. Le travail minutieux des centres de TxP portant sur la sélection des donneurs et des receveurs d’un greffon pulmonaire ainsi que de l’ensemble des efforts fournis pour relever les défis de la prise en charge chirurgicale, péri-opératoire et la gestion des complications médicales de la TxP à plus long terme ont permis une augmentation du nombre de procédures et l’amélioration du pronostic post-TxP. Les membres du groupe de travail de la Société de pneumologie de langue française (SPLF) ont réalisé une mise à jour des données connues de la littérature et analysé les facteurs de risque qui limitent les chances de survie après la TxP. L’objectif de ce travail a été de guider les pneumologues dans leur prise en charge de l’insuffisance respiratoire terminale, de les aider à identifier les patients potentiellement éligibles à la TxP et de déterminer selon quels délais les adresser à centre de TxP. Les objectifs de la TxP demeurent l’allongement de la vie et l’amélioration de la qualité de vie des malades. Les propositions faites dans ce document portent sur une ressource limitée et restent guidées par des principes éthiques décrits plus loin.

Published
2022

21. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study

Author

S Papiris, I Campo, F Mariani, M Kallieri, L Kolilekas, A I Papaioannou, E G Chousein, E Cetinkaya, F Bonella, R Borie, M Kokosi, T Pickworth, M Molina-Molina, M Gasa, E Radzikowska, J Fijolek, S Jouneau, E Gomez, C Mccarthy, E Bendstrup, W J Piotrowski, R Pabary, A Hadchouel, N Coolen-Allou, T Alfaro, C R Cordeiro, E Antonogiannaki, I P Tomos, D Papakosta, T Kontakiotis, P Panagiotou, K Douros, A Schams, S Lettieri, V Papaevangelou, C Kanaka-Gantenbein, A Karakatsani, S Loukides, U Costabel, B Crestani, C Morgan, R Tazawa, A Bush, M Griese, and E D Manali

Published
2022

27. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events

Author

Nadine Lemaître, Jérôme Robert, N. Fortineau, C. Verdet, P. Morand, S. Gallien, O. Bouchaud, P. Sellier, K. Lacombe, Frédéric Schramm, A. Hummel, F. Mechaï, Valérie Pourcher, J.-L. Meynard, V. Delcey, J. Lourenco, J.-M. Molina, J.-W. Decousser, A. Ferroni, Christophe Rioux, T. Billard-Pomares, V. Lalande, B. Wyplosz, Dhiba Marigot-Outtandy, D. Le Dû, F. Cohen, G. Pialoux, C. Pierre-Audigier, H. Nunes, E. Catherinot, Lorenzo Guglielmetti, L. Lassel, B. Denis, M. Gominet, Nicolas Veziris, B. Crestani, V. Chambrin, Eric Caumes, L. Deconinck, R. Guéry, Yazdan Yazdanpanah, A.-L. Roux, C. Guillet, A.-L. Munier, B. Nebbad-Lechani, F. Morel, C. Le Jeunne, N. Grall, M. Lafaurie, Hugo Langris, E. Carbonnelle, E. Bille, N. Lemaitre, S. Abgrall, M. Pellan, Faiza Mougari, I. Bonnet, A.-S. Morin, P. Loulergue, Marwa Bachir, Sheila Chiesi, J. Jaffré, Alexandra Aubry, A.-L. Nardi, J. Dumoulin, S. Bulifon, C. Londner, N. Roche, M. Jachym, A. Canestri, J. Pavie, Simone Tunesi, A. Galy, N. De Castro, B. Fantin, J.D. Lelièvre, C. Dumesnil, Typhaine Billard-Pomares, E. Lecorché, Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Université de Caen Normandie (UNICAEN), Normandie Université (NU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Strasbourg, CHU Amiens-Picardie, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière] (CNR-MyRMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], and Gestionnaire, Hal Sorbonne Université

Subjects
Adult, Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Tuberculosis, [SDV]Life Sciences [q-bio], 030106 microbiology, Antitubercular Agents, Infectious and parasitic diseases, RC109-216, Drug resistance, World health, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Drug Resistance, Bacterial, Epidemiology, Isoniazid, medicine, Humans, 030212 general & internal medicine, Adverse effect, drug resistance, business.industry, Mycobacterium tuberculosis, General Medicine, Middle Aged, medicine.disease, 3. Good health, Factors treatment, [SDV] Life Sciences [q-bio], Treatment Outcome, Infectious Diseases, Streptomycin, Case-Control Studies, epidemiology, Female, France, business, medicine.drug
Abstract

Objectives Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.

Published
2021

28. Les J2R 2022 de retour à Reims

Author

I. Vachier, B. Crestani, P. Chanez, and J. Gonzalez

Subjects
Pulmonary and Respiratory Medicine
Published
2023

31. Prévalence du cancer du poumon dans une cohorte de patients porteurs d’une mutation d’un gène lié au surfactant

Author

A. Brudon, M. Legendre, A. Mageau, N. Nathan, J. Bermudez, D. Bouvry, J. Cadranel, A. Cazes, B. Crestani, T. Dégot, C. Delestrain, R. Diesler, R. Epaud, M.P. Debray, P. Fanen, A. Gaubert, E. Manali, A. Gondouin, A. Guillaumot, S. Hirschi, S. Leroy, S. Marchand-Adam, H. Nunes, S. Amselem, C. Picard, G. Prevot, M. Reynaud, P. De Vuyst, L. Wémeau-Stervinou, G. Zalcman, V. Cottin, and R. Borie

Subjects
Pulmonary and Respiratory Medicine
Published
2023

32. Effet protecteur du FGF21 dans la fibrose pulmonaire

Author

M. Ghanem, G. Archer, A. Justet, M. Hachem, T. Boghanim, A. Vadel, N. Poté, A. Cazes, P. Mordant, Y. Castier., H. Mal, M. Jaillet, A. Mailleux, and B. Crestani

Subjects
Pulmonary and Respiratory Medicine
Published
2023

34. Neumotórax espontáneo

Author

P. Le Guen, B. Crestani, and P. Mordant

Subjects
Ocean Engineering, Safety, Risk, Reliability and Quality
Published
2021

35. Pneumotorace spontaneo

Author

P. Le Guen, B. Crestani, and P. Mordant

Subjects
General Medicine
Published
2021

39. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version courte

Author

V. Cottin, P. Bonniaud, J. Cadranel, B. Crestani, S. Jouneau, S. Marchand-Adam, H. Nunes, L. Wémeau-Stervinou, E. Bergot, E. Blanchard, R. Borie, A. Bourdin, C. Chenivesse, A. Clément, E. Gomez, A. Gondouin, S. Hirschi, F. Lebargy, C.-H. Marquette, D. Montani, G. Prévot, S. Quetant, M. Reynaud-Gaubert, M. Salaun, O. Sanchez, B. Trumbic, K. Berkani, P.-Y. Brillet, M. Campana, L. Chalabreysse, G. Chatté, D. Debieuvre, G. Ferretti, J.-M. Fourrier, N. Just, M. Kambouchner, B. Legrand, F. Le Guillou, J.-P. Lhuillier, A. Mehdaoui, J.-M. Naccache, C. Paganon, M. Rémy-Jardin, S. Si-Mohamed, P. Terrioux, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Pneumologie et Allergie - Hôpital Nord [Marseille], Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

Subjects
Pulmonary and Respiratory Medicine, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

40. Retour d’expérience sur la direction médicale de crise à l’Assistance publique–Hôpitaux de Paris pendant la crise Covid-19

Author

Olivier Langeron, B. Crestani, Frédéric Adnet, A. Cariou, Bruno Riou, M. Raux, and J. Duranteau

Subjects
03 medical and health sciences, 0302 clinical medicine, Emergency Medicine, 030208 emergency & critical care medicine, 030204 cardiovascular system & hematology
Abstract

Un retour d’expérience sur la direction médicale de crise (DMC) pendant la première phase de l’épidémie de Covid-19 a été effectué à l’Assistance publique–Hôpitaux de Paris (AP–HP), le plus important centre hospitalier universitaire européen. L’AP–HP s’est dotée d’un directeur médical de crise (DMC) AP–HP, de six DMC de groupes hospitaliers (GH) et d’un DMC pour chacun des 39 sites hospitaliers. Le pilotage s’est appuyé sur des réunions quotidiennes de crise AP–HP et de GH, des groupes de travail disciplinaires et des tableaux de bord quotidiens fiabilisés qui ont permis d’optimiser les actions. Des actions innovantes ont été mises en place : cellules de régulation des entrées et des sorties de réanimation, suivi des patients infectés à domicile, traçage des contacts, transferts interrégionaux de patients de réanimation. Les éléments clés de la réussite ont été les relations entre direction générale et DMC, l’articulation entre l’échelon central (AP–HP) et celui des GH, la mobilisation de tous les acteurs vers un objectif unique identifié et la mobilisation de l’ensemble des soignants, y compris les étudiants. Parmi les pistes d’amélioration soulignées, il convient de citer la généralisation des DMC hors AP–HP, conformément à la réglementation, le développement de la connaissance du mode de fonctionnement de crise, l’anticipation de la formation à la gestion de crise, la réalisation d’une information quotidienne de l’ensemble des acteurs des actions menées dans une crise de longue durée et la participation des représentants des usagers. La gestion de la recherche en temps de crise reste à inventer au niveau national, voire européen.

Published
2020

44. Les pneumopathies interstitielles diffuses de la polyarthrite rhumatoïde sont associées à une taille plus courte des télomères et un excès de variants rares au sein de gènes impliqués dans les téloméropathies

Author

L. Kawano, P.A. Juge, T. Doyle, A. Walts, B. Granger, R. Borie, C. Kannengiesser, M. Soubrier, V. Dominique, C. Boileau, L. Wemeau-Stervinou, M.P. Debray, S. Marchand-Adam, C. Richez, H. Nunes, R.M. Flipo, T. Schaeverbeke, N. Saidenberg-Kermanac’h, L. Joyce, B. Crestani, and P. Dieudé

Subjects
Rheumatology
Published
2022

46. Excès de variants rares délétères au sein de gènes appartenant à la voir JAK-STAT chez des patients atteints de pneumopathie interstitielle diffuse associée à la polyarthrite rhumatoïde

Author

P.A. Juge, S. Gazal, R. Borie, L. Wemeau-Stervinou, M.P. Debray, S. Ottaviani, S. Marchand-Adam, C. Richez, H. Nunes, P. Richette, C. Kannengiesser, P. Froguel, J. Avouac, J. Sibilia, R.M. Flipo, V. Cottin, T. Schaeverbeke, M. Soubrier, N. Saidenberg-Kermanac’h, V. Dominique, C. Boileau, B. Crestani, and P. Dieudé

Subjects
Rheumatology
Published
2022

50. Association rituximab et mycophenolate mofetil chez les patients avec une pneumopathie interstitielle non spécifique : essai contrôlé randomisé en double aveugle, contre mycophenolate mofetil et placebo (Ever-Ild)

Author

J. Mankikian, A. Caille, M. Reynaud-Gaubert, J. Leger, P. Bonniaud, P.Y. Brillet, J. Cadranel, I. Court-Fortune, B. Crestani, M.P. Debray, E. Gomez, A. Gondouin, S. Hirschi-Santelmo, D. Israel-Biet, S. Jouneau, C.H. Marquette, J.M. Naccache, H. Nunes, L. Plantier, G. Prevot, S. Quetant, J. Traclet, L. Wemeau, T. Angoulvant, V. Cottin, and S. Marchand-Adam

Subjects
Pulmonary and Respiratory Medicine
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results